An exome-wide study of renal operational tolerance

Front Med (Lausanne). 2023 May 17:9:976248. doi: 10.3389/fmed.2022.976248. eCollection 2022.

Abstract

Background: Renal operational tolerance is a rare and beneficial state of prolonged renal allograft function in the absence of immunosuppression. The underlying mechanisms are unknown. We hypothesized that tolerance might be driven by inherited protein coding genetic variants with large effect, at least in some patients.

Methods: We set up a European survey of over 218,000 renal transplant recipients and collected DNAs from 40 transplant recipients who maintained good allograft function without immunosuppression for at least 1 year. We performed an exome-wide association study comparing the distribution of moderate to high impact variants in 36 tolerant patients, selected for genetic homogeneity using principal component analysis, and 192 controls, using an optimal sequence-kernel association test adjusted for small samples.

Results: We identified rare variants of HOMER2 (3/36, FDR 0.0387), IQCH (5/36, FDR 0.0362), and LCN2 (3/36, FDR 0.102) in 10 tolerant patients vs. 0 controls. One patient carried a variant in both HOMER2 and LCN2. Furthermore, the three genes showed an identical variant in two patients each. The three genes are expressed at the primary cilium, a key structure in immune responses.

Conclusion: Rare protein coding variants are associated with operational tolerance in a sizable portion of patients. Our findings have important implications for a better understanding of immune tolerance in transplantation and other fields of medicine.ClinicalTrials.gov, identifier: NCT05124444.

Keywords: Homer2; IQCH; LCN2; NGAL; exome sequencing; operational tolerance; primary cilium; renal transplantation.

Associated data

  • ClinicalTrials.gov/NCT05124444

Grants and funding

AM was supported by the Fonds Erasme; the Fonds de la Recherche Scientifique Médicale (FRSM, PDR 23670170); the Fonds Carine VYGHEN; and the Fonds Horlait-Dapsens). MA was supported by the Belgian FNRS (T.0174.15); and Fonds Erasme. RD was supported by a Marie Skłodowska-Curie fellowship (IF-EF) from the European Union's Horizon 2020 research and innovation program under Grant Agreement No. 706296 and the ANR project KTD-innov (ANR-17-RHUS-0010) thanks to the French government financial support managed by the French National Research Agency (ANR) within investments into the future program. This work was performed in the context of the IHU-Cesti project (ANR-10-IBHU-005), the DHU Oncogreffe, the LabEx IGO program (no. ANR-11-LABX-0016), the ANR project PRELUD (ANR-18-CE17-0019) and the ANR project BIKET (ANR-17-CE17-0008). The IHU-Cesti project was also supported by Nantes Métropole and Région Pays de la Loire. The laboratory received funding from the European Union's Horizon 2020 Research and Innovation Program under Grant Agreement No. 754995. OV was supported by the Ministry of Health of the Czech Republic (NV19-06-00031). TOMOGRAM was also supported logistically and financially by the ERA-EDTA – DESCARTES working group, the Department of Nephrology at Antwerp University Hospital, Belgium and the Institute for Clinical and Experimental Medicine (IKEM) in Prague, Czech Republic. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Open access funding provided by University of Geneva.